JERUSALEM--(BUSINESS WIRE)--Nov. 12, 2012--
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical
development company, announced that it will host an Analyst & Investor
Day on Tuesday, December 4, 2012 in New York City beginning at 8:00 am
The Company’s management team and various key opinion leaders will host
a series of presentations discussing selected compounds from BioLineRx’s
The presentations will begin at 8:30 am EST and conclude at
approximately 1:30 pm EST. A recording of the presentations will be
available after the event, through the Investor Relations section of
BioLineRx’s website, www.biolinerx.com,
and at www.kcsa.com.
Analysts and qualified investors who would like to register or learn
more about the event should contact Diane Imas of KCSA Strategic
Communications at (212) 896-1242 or email@example.com.
Registration is required as space is limited.
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx’s current portfolio consists of six clinical stage candidates:
BL-1020 for schizophrenia is currently undergoing a Phase II/III study;
BL-1040, for prevention of pathological cardiac remodeling following a
myocardial infarction, which has been out-licensed to Ikaria Inc., is
currently undergoing a pivotal CE-Mark registration trial; BL-5010 for
non-surgical removal of skin lesions has completed a Phase I/II study;
BL-1021 for neuropathic pain is in Phase I development, BL-7040 for
treating inflammatory bowel disease (IBD) is currently undergoing a
Phase II trial, and BL-8040 for treating acute myeloid leukemia (AML)
and other hematological cancers has completed Phase I. In addition,
BioLineRx has nine products in various pre-clinical development stages
for a variety of indications, including central nervous system diseases,
infectious diseases, cardiovascular and autoimmune diseases.
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government’s Office of the Chief Scientist (OCS). The final stage
includes partnering with medium and large pharmaceutical companies for
advanced clinical development (Phase III) and commercialization. For
more information on BioLineRx, please visit www.biolinerx.com.
Source: BioLineRx Ltd.
KCSA Strategic Communications
Garth Russell / Todd Fromer
212-896-1250 / 1 212-896-1215
firstname.lastname@example.org / email@example.com